Search research articles
Contact Us
Filters
Showing results (81-90 of 115) with videos related to
Page
of 12
Sort By:
Molecular Cancer Research : MCR
|
September 23, 2022
ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer
Alexandra McMellen, Tomomi M Yamamoto, Lubna Qamar, et al.
Cancer Research Communications
|
December 4, 2025
SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
Bradley R Corr, Elizabeth R Woodruff, Tomomi M Yamamoto, et al.
Cancer Research Communications
|
March 7, 2024
Targeting Tryptophan Catabolism in Ovarian Cancer to Attenuate Macrophage Infiltration and PD-L1 Expression
Lyndsey S Crump, Jessica L Floyd, Li-Wei Kuo, et al.
Biorxiv : the Preprint Server for Biology
|
May 4, 2026
On the predictability of progression-free survival in ovarian cancer from NanoString gene expression data
Lucy B Van Kleunen, Grace Bowman, Sarah Elizabeth Stockman, et al.
Gynecologic Oncology
|
July 23, 2025
A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer
Bradley R Corr, Ashley Haggerty, Stefan M Gysler, et al.
Cancer Immunology Research
|
August 8, 2024
The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Lucy B Van Kleunen, Mansooreh Ahmadian, Miriam D Post, et al.
Cancer Research Communications
|
July 10, 2024
Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma
Ritsuko Iwanaga, Tomomi M Yamamoto, Karina Gomez, et al.
Genes & Development
|
November 5, 2025
Mutant p53 binds and controls estrogen receptor activity to drive endocrine resistance in ovarian cancer
Chunlei Shao, Alexandra Indeglia, Maya Foster, et al.
Cell Reports
|
March 29, 2018
Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer
Takeshi Fukumoto, Pyoung Hwa Park, Shuai Wu, et al.
Briefings in Bioinformatics
|
February 10, 2026
Bayesian multi-cell type models for the analysis of complex immune cell populations with application to ovarian cancer
Chase J Sakitis, Jose Laborde, Julia Wrobel, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 115) with videos related to
Sort By:
Page
of 12
Molecular Cancer Research : MCR
|
September 23, 2022
ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer
Alexandra McMellen, Tomomi M Yamamoto, Lubna Qamar, et al.
Cancer Research Communications
|
December 4, 2025
SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
Bradley R Corr, Elizabeth R Woodruff, Tomomi M Yamamoto, et al.
Cancer Research Communications
|
March 7, 2024
Targeting Tryptophan Catabolism in Ovarian Cancer to Attenuate Macrophage Infiltration and PD-L1 Expression
Lyndsey S Crump, Jessica L Floyd, Li-Wei Kuo, et al.
Biorxiv : the Preprint Server for Biology
|
May 4, 2026
On the predictability of progression-free survival in ovarian cancer from NanoString gene expression data
Lucy B Van Kleunen, Grace Bowman, Sarah Elizabeth Stockman, et al.
Gynecologic Oncology
|
July 23, 2025
A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer
Bradley R Corr, Ashley Haggerty, Stefan M Gysler, et al.
Cancer Immunology Research
|
August 8, 2024
The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Lucy B Van Kleunen, Mansooreh Ahmadian, Miriam D Post, et al.
Cancer Research Communications
|
July 10, 2024
Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma
Ritsuko Iwanaga, Tomomi M Yamamoto, Karina Gomez, et al.
Genes & Development
|
November 5, 2025
Mutant p53 binds and controls estrogen receptor activity to drive endocrine resistance in ovarian cancer
Chunlei Shao, Alexandra Indeglia, Maya Foster, et al.
Cell Reports
|
March 29, 2018
Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer
Takeshi Fukumoto, Pyoung Hwa Park, Shuai Wu, et al.
Briefings in Bioinformatics
|
February 10, 2026
Bayesian multi-cell type models for the analysis of complex immune cell populations with application to ovarian cancer
Chase J Sakitis, Jose Laborde, Julia Wrobel, et al.
Page
of 12